Clinical Trials Arena July 25, 2024
The company plans to use the funds to conduct an early feasibility study and a pivotal trial for its transfemoral tricuspid heart valve replacement system, Topaz.
European device company TRiCares has raised $50m in a Series D financing round to develop its transfemoral tricuspid heart valve replacement system, Topaz.
The company plans to use the funds to conduct an early feasibility study in the US and initiate a pivotal trial in Europe. Additionally, the investment will be used to develop more valve sizes for Topaz. The Series D funds were raised from a single, strategic unnamed investor.
TRiCares has received an Investigational Device Exemption (IDE) from the US Food and Drug Administration (FDA) to conduct an early feasibility study, due...
Today's Sponsors
Today's Sponsor